DF/HCC Program Affiliation

Breast Cancer
Outcomes Research
Biostatistics

Research Abstract

Dr. Gelber co-developed the Q-TWiST method (Quality-adjusted Time Without Symptoms of disease or Toxicity of treatment) for incorporating quality-of-life considerations into treatment comparisons. This quality-adjusted survival technique provides a framework to balance the benefits of disease control against the
burdens of treatment side effects using threshold utility analysis and patient preferences. The method has been applied to treatment comparisons for patients with breast cancer, rectal cancer, HIV infection, brain tumors, childhood acute myeloid leukemia and melanoma.

Dr. Gelber's research includes interpretations of meta-analysis and evaluations of successful treatments for childhood cancers. In addition, he is responsible for the design, conduct, analysis and reporting of large scale randomized clinical trials evaluating treatments for breast cancer, pediatric malignancies and perinatal transmission of HIV.

Publications

• Jordan VC, Gelber RD.Problems with the progesterone receptor in practice?.J Clin Oncol 2007 May 20;25(15):1957-9.
  17452674
• Mauriac L, Keshaviah A, Debled M, Mouridsen H, Forbes J, Thürlimann B, Paridaens R, Monnier A, Láng I, Wardley A, Nogaret JM, Gelber R, Castiglione-Gertsch M, Price K, Coates A, Smith I, Viale G, Rabaglio M, Zabaznyi N, Goldhirsch A.Predictors of early re
  17301074
• Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A.CA15-3 and alkaline phosphatase as predic
  17237474
• Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B,.Re-evaluating adjuvant breast canc
  17077359
• Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A,.Identifying breast cancer patients at risk for Central Nervous System
  16603601
• Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD,.Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.J
  16505417
• Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL.Prospective study of wide excision alone for ductal carcinoma in situ of the breast.J Clin Oncol 2006 Mar 1;24(7):1031-6.
  16461781
• Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, Coates AS, Gelber RD, Aebi S, Castiglione-Gertsch M, Viale G, Price KN, Goldhirsch A,.Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of I
  16421418
• Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Wardly A, Price KN, Goldhirsch A,.A comparison of letrozole and tamoxifen in postmenopausal women with
  16382061
• Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione-Gertsch M, Goldhirsch A, Coates AS, Ravaioli A,.Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cance
  16369994
• Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS,.Randomized trial comparing axillary clearance versus no axillary clearance in older
  16344321
• Regan MM, Gelber RD.Predicting response to systemic treatments: learning from the past to plan for the future.Breast 2005 Dec;14(6):582-93.
  16199162